EnteroMedics seeks to raise $14.5m to support US approval of Maestro
This article was originally published in Clinica
Executive Summary
Obesity device developer EnteroMedics has announced plans to raise $14.5m in a public offering to support US regulatory approval of its Maestro weight-loss device. The company will also use the proceeds for international commercialisation efforts, clinical product development activities and general corporate purposes.